Biolegend, 100737, Brilliant Violet 421™ anti-mouse CD8a Antibody
125microl
Catalog Number: 100737
Send an RFQ.
Category
| Verified Reactivity | Mouse |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Rat |
| Immunogen | Mouse thymus or spleen |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA). |
| Preparation | The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. |
| Concentration | µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.) |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested IHC - Verified SB - Reported in the literature, not verified in house |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Recommended Usage |
|---|
| Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. |
| Excitation Laser | Violet Laser (405 nm) |
|---|
| Application Notes | Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746). |
|---|
| Additional Product Notes | Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH). |
|---|
| Application References(PubMed link indicates BioLegend citation) | Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed |
|---|
| Product Citations | Jayachandran R, et al. 2019. Immunity. 50:152. PubMed Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed Ho HM, et al. 2022. Pharmaceutics. 14:. PubMed Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed Yi J, et al. 2023. Nat Commun. 14:1941. PubMed Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed Wang X, et al. 2023. Nat Commun. 14:3440. PubMed Guo X, et al. 2023. Mol Immunol. 160:32. PubMed Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed Yang J, et al. 2022. Mol Ther Nucleic Acids. 30:184. PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Xu Y, et al. 2023. EMBO Rep. 24:e55503. PubMed Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed Xiao R, et al. 2022. J Immunol. 208:2109. PubMed McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed Gabriely G, et al. 2021. iScience. 24:103347. PubMed Nguyen NDNT, et al. 2020. NPJ Vaccines. 5:7. PubMed Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed Lee J, et al. 2020. Gut Microbes. 1:. PubMed Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed Stathopoulou C, et al. 2020. Immunity. 49(2):247-263.e7.. PubMed Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed Franks SE, et al. 2019. J Immunol. 202:3381. PubMed Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed Lutes LK, et al. 2021. eLife. 10:00. PubMed Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed Lees JG, et al. 2020. PLoS One. 15:e0238164. PubMed Helm M, et al. 2022. Life (Basel). 12:. PubMed Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Ding Z, Dahlin J 2016. Sci Rep. 6:28290. PubMed Wang C, et al. 2021. Cell Rep. 37:110021. PubMed Woodworth JS, et al. 2021. Nat Commun. 12:6658. PubMed Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed Stokes J, et al. 2020. Oncoimmunology. 9:1758011. PubMed MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed Miller IC, et al. 2021. Nature Biomedical Engineering. :. PubMed Köchl R, et al. 2020. Elife. 9:00. PubMed Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed Park D, et al. 2020. Cancer Res. 80:4172. PubMed Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed Hutter K, et al. 2020. FEBS J. . PubMed Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed Imani J, et al. 2021. JCI Insight. 6:. PubMed Lu X, et al. 2020. Sci Transl Med. 12:. PubMed Guo P, et al. 2021. J Immunol. 207:408. PubMed Knizkova D, et al. 2022. Nat Immunol. 23:1644. PubMed Bambouskova M, et al. 2021. Cell Reports. 34(10):108756. PubMed Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed Sum E, et al. 2021. Clin Cancer Res. 27:4036. PubMed Chen Z, et al. 2014. Cancer Immunol Res. 2:911. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed Sinclair LV, et al. 2020. Immunometabolism. 2:e200029. PubMed LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed Hu-Lieskovan S, et al. 2015. Sci Transl Med. 7:279. PubMed Ballet R, et al. 2014. PLoS Pathog. 10:1004550. PubMed Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed Giampazolias E, et al. 2021. Cell. . PubMed Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed Zwick M, et al. 2019. Front Immunol. 10:222. PubMed Klepsch V, et al. 2018. Nat Commun. 9:1538. PubMed Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed Dong X, et al. 2022. Front Immunol. 13:896472. PubMed Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed Briukhovetska D, et al. 2020. Frontiers in Immunology. 1.428472222. PubMed Pavelko K, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01532. PubMed Zheng Y, et al. 2022. J Immunol. 208:501. PubMed Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed Heil J, et al. 2021. Nat Commun. 12:6963. PubMed Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed Iwanami N, et al. 2020. iScience. 23:101260. PubMed Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed Li Q, et al. 2022. J Biol Chem. :101753. PubMed Corrado M, et al. 2020. Cell Metab. 32:981. PubMed Dammeijer F, et al. 2020. Cancer Cell. 38(5):685-700.e8. PubMed Young A, et al. 2017. Cancer Res. 77:4684. PubMed Liang Z, et al. 2022. iScience. 25:105233. PubMed |
|---|
| RRID | AB_10897101 (BioLegend Cat. No. 100737) AB_2562558 (BioLegend Cat. No. 100753) AB_11204079 (BioLegend Cat. No. 100738) |
|---|
| Structure | Ig superfamily, CD8α chain, 34 kD |
|---|
| Distribution | Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells |
|---|
| Function | Co-receptor for TCR |
|---|
| Ligand/Receptor | MHC class I molecule |
|---|
| Antigen References | 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523. |
|---|
| Gene ID | 12525 |
|---|
| UniProt | View information about CD8alpha on UniProt.org |
|---|
| Clone | 53-6.7 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | T8, Lyt2, Ly-2 |
|---|
| Isotype | Rat IgG2a, κ |
|---|